AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 111 filers reported holding AKERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 8.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $222,729 | -35.9% | 9,494 | -31.0% | 0.00% | – |
| Q1 2024 | $347,729 | +25.1% | 13,766 | +15.6% | 0.00% | – |
| Q4 2023 | $278,052 | -53.1% | 11,908 | +1.6% | 0.00% | – |
| Q3 2023 | $593,051 | +11.6% | 11,725 | +3.0% | 0.00% | – |
| Q2 2023 | $531,613 | +30.3% | 11,386 | +6.8% | 0.00% | – |
| Q1 2023 | $407,851 | -20.4% | 10,660 | +14.0% | 0.00% | – |
| Q4 2022 | $512,215 | +112.5% | 9,347 | +32.4% | 0.00% | – |
| Q3 2022 | $241,000 | +7.6% | 7,060 | -8.4% | 0.00% | – |
| Q1 2021 | $224,000 | – | 7,709 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 423,849 | $9,943,498 | 11.19% |
| Propel Bio Management, LLC | 327,752 | $7,689,062 | 4.99% |
| GENERAL ATLANTIC, L.P. | 5,233,989 | $122,789,382 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 625,087 | $14,664,541 | 3.46% |
| Yiheng Capital Management, L.P. | 1,434,179 | $33,645,839 | 2.71% |
| Redmile Group, LLC | 1,614,473 | $37,875,537 | 2.29% |
| Boxer Capital, LLC | 1,676,733 | $39,336,156 | 2.07% |
| RTW INVESTMENTS, LP | 5,431,985 | $127,434,368 | 1.97% |
| Logos Global Management LP | 800,000 | $18,768,000 | 1.52% |
| MPM BioImpact LLC | 385,990 | $9,055,325 | 1.41% |